Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
The company has been sold to Shinshin Pharmaceuticals
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The segment delivered strong sales growth of 20% YoY
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
To prevent the state from facing a shortage of medical oxygen and to bolster the existing infrastructure, the SRAM & MRAM group is actively helping the state government to set up oxygen plants in multiple cities
The company to receive upfront and milestone payments, in addition to royalties
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Subscribe To Our Newsletter & Stay Updated
